Клинико-фармакологическое обоснование выбора лекарственного средства для заместительной гормональной терапии в пери- и постменопаузе

1. Elfituri A, Sherif F, Elmahaishi M, Chrystyn H. Two hormone replacement therapy (HRT) regimens for middle-eastern postmenopausal women. Maturitas 2005; 52 (1): 52–9.
2. Калинченко C.Ю., Апетов С.С. Выбор оптимального препарата для заместительной гормональной терапии у женщин в перименопаузе и постменопаузе. Гинекология. 2010; 4 (12).
3. Borowiecka M, Polac I, Nowak P et al. Changes in hemostatic parameters after oral hormone therapy in postmenopausal women. J Womens Health (Larchmt) 2010; 19 (12): 2267–70.
4. Schenck-Gustafsson K, Brincat M, Erel CT et al. EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas 2011; 68 (1): 94–7.
5. Stevenson JC, Durand G, Kahler E, Pertyński T. Oral ultra-low dose continuous combined hormone replacement therapy with 0,5 mg 17b-oestradiol and 2,5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas 2010; 67 (3): 227–32.
6. Frequently asked questions about hormone therapy. New re-commendations based on ACOG's Task Force Report on Hormone Therapy. Available at www.acog.org. Accessed March 1, 2005.
7. Martins W de P, dos Reis RM, Ferriani RA et al. Endometrial preparation for in vitro oocyte maturation: early use of estrogen increases endometrial tissue and requires lower daily dosage: a cross over trial in «mock» cycles. J Assist Reprod Genet 2006; p.  241–6.
8. Scheen AJ, Gaspard U. Medication of the month. Femoston Low (0,5 mg estradiol plus 2,5 mg dydrogesterone) for menopausal hormonal replacement therapy. Rev Med Liege 2011; 66 (4): 209–14.
9. Rousseau A, Robert A, Gerotziafas G et al. Effect of two oral doses of 17beta-estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized double-blind placebo-controlled study. Fundam Clin Pharmacol 2010; 24 (2): 239–45.
10. Организация службы мониторинга безопасности лекарственных средств (фармаконадзора) в компаниях- производителях лекарственных средств или держателях регистрационных удостоверений. Методич. рекомендации Федеральной службы по надзору в сфере здравоохранения и социального развития. 2008.
11. Торшин И.Ю., Громова О.А., Сухих Г.Т. и др. Молекулярные механизмы дидрогестерона (Дюфастон). Полногеномное исследование транскрипционных эффектов рецепторов прогестерона, андрогенов и эстрогенов. Гинекология. 2010; 5: 9–16.
12. Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium Maturitas 2009; (Suppl. 1): 3–11.
13. De Franciscis P, Cobellis L, Fornaro F et al. Low-dose hormone therapy in the perimenopause. Int J Gynaecol Obstet 2007; 98 (2): 138–42.
14. Post MS, Verhoeven MO, van der Mooren MJ et al. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab 2003; 88 (9): 4221–6.
15. Mueck AO, Seeger H, Bühling KJ. Use of dydrogesterone in hormone replacement therapy. Maturitas 2009; (Suppl. 1): 51–60.
16. de Kraker AT, Kenemans P, Smolders RG, Kroeks MV. Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol 2009; 142 (2): 139–44.
17. Lambrinoudaki I, Brincat M, Erel CT et al. EMAS position statement: managing obese postmenopausal women. Maturitas 2010; 66 (3): 323–26.
18. Quereux C, Pornel B, Bergeron C, Ferenczy A. Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile. Maturitas 2006; 53 (3): 299–305.
19. Зайдиева Я.З. Проблема маточных кровотечений на фоне заместительной гормональной терапии у женщин в климактерии. http:old.consilium-medicum.com/media/consilium/07_06/71.shtml
20. Bergeron C, Nogales FF, Rechberger T et al. Ultra low dose continuous combined hormone replacement therapy with 0.5mg 17beta-oestradiol and 2.5mg dydrogesterone: protection of the endometrium and amenorrhoea rate. Maturitas 2010; 66 (2): 201–5.
21. Gadducci A, Biglia N, Cosio S et al. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. Gynecol Endocrinol 2009; 25 (12): 807–15.
22. Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O. Endometrial cancer in postmenopausal women using estradiol-progestin therapy Obstet Gynecol 2009; 114 (6): 1197–204.
23. Cieraad D, Conradt C, Jesinger D, Bakowski M. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms. Arch Gynecol Obstet 2006; 274 (2): 74–80.
24. Stevenson JC, Rioux JE, Komer L, Gelfand M. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women. Climacteric 2005; 8 (4): 352–9.
25. Clarkson TB, Appt SE. Controversies about HRT-lessons from monkey models. Maturitas 2005; 51: 64–74.
26. Ouyang P, Michos E, Karas R. Hormone replacement therapy and the cardiovascular system. Lessons learned and unanswered questions. J Am Coll Cardiol 2006; 47: 1741–53.
27. Maffei S, Mercuri A, Prontera C et al. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy. Climacteric 2006; 9 (6) 452–8.
28. Gambacciani M, Monteleone P, Vitale C et al. Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: a randomised clinical trial. Maturitas 2002; 43 (2): 117–23.
29. Жлоба А.А. Роль АДМА в качестве эндогенного ингибитора eNOS и одного из медиаторов развития вазомоторной эндотелиальной дисфункции. Обзор. Регионарное кровообращение и микроциркуляция. 2007; 3 (23): 4–14.
30. Post MS, Rosing J, Van Der Mooren MJ et al. Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. Br J Haematol 2002; 119 (4): 1017–123.
31. Chiantera V, Sarti CD, Fornaro F et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003; 10 (4): 286–91.
32. Kaya C, Dinçer Cengiz S, Cengiz B, Akgün G. The long-term effects of low-dose 17 beta-estradiol and dydrogesterone hormone replacement therapy on 24-h ambulatory blood pressure in hypertensive postmenopausal women: a 1-year randomized, prospective study. Climacteric 2006; 9 (6): 437–45.
33. Proudler AJ, Cooper A, Whitehead M, Stevenson JC. Effects of oestrogen-only and oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women. Clin Endocrinol (Oxf) 2003; 58 (1): 30–5.
34. Bain CA, Walters MR, Lees KR, Lumsden MA. The effect of HRT on cerebral haemodynamics and cerebral vasomotor reactivity in post-menopausal women. Hum Reprod 2000; 19 (10): 2411–4.
35. Vitale C, Cornoldi A, Gebara O et al. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause 2005; 12 (5): 552–8.
36. Sator PG, Sator MO, Schmidt JB et al. A prospective, randomized, double-blind, placebo-controlled study on the influence of a hormone replacement therapy on skin aging in postmenopausal women. Climacteric 2007; 10 (4): 320–334.
37. Hall G, Phillips TJ. Estrogen and skin: the effects of of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol 2005; 53: 558–68.
38. Юренева С.В., Ильина Л.М., Муллабаева С.М. Кожа и половые гормоны (эффекты менопаузы и заместительной гормональной терапии). Пластич. хирургия и косметология. 2011 (4): 1–10.

Е.В.Елисеева, Ю.В.Феоктистова, И.И.Шмыкова 

Кафедра общей и клинической фармакологии ГОУ ВПО ВГМУ Минздравсоцразвития РФ, Владивосток